Skip to content
Brand AI

Gilead Sciences

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile4 entries

  1. 2022

    Dispute over 340B contract-pharmacy restrictions

    AIDS Healthcare Foundation publicly accused Gilead of unlawfully restricting access to certain medicines through 340B contract pharmacies and used the term “Greediad” in advocacy advertising. The supplied source documents the organization’s allegations and campaign, not a final legal determination.

    Source

  2. 2021

    Patients sue Gilead over alleged toxicity and disclosure of HIV drug risks

    Lawsuit filed

    Patients with HIV brought a civil suit against Gilead, accusing the company of failing to properly report potential health effects of its HIV drugs and alleging that the drugs caused kidney and bone problems. The claims are allegations by the plaintiffs, not a court determination.

    Source excerpt

    • The plaintiffs cited kidney and bone deficiencies as a side effect and seek compensation for past and future damages caused by the products
    • On Friday, a civil suit was brought against pharmaceutical company Gilead for it’s failure to properly report potential health effects of the numerous HIV drugs they had released to the public between 2001 and 2015.
    Source

  3. 2020

    Gilead responds to questions about remdesivir trials and patents

    Company response

    Gilead issued a statement addressing questions about remdesivir, saying it had reached an agreement with Chinese health authorities to support two clinical trials and that it holds patents for the drug in China, the United States and elsewhere. It also said the China patent application for coronavirus use was pending approval.

    Company response

    • Clarification — 吉利德科学

      2月8日，吉利德科学就瑞德西韦专利等事项发表声明指出，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床试验。

    Source excerpt

    • 2月8日，吉利德科学就瑞德西韦专利等事项发表声明指出，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床试验。
    • 吉利德研发了瑞德西韦，并在美国、中国及世界其他地区拥有专利。
    • 在中国，对于冠状病毒应用的专利申请尚待批准。
    Source

  4. 2019

    U.S. government sues Gilead over PrEP patent rights

    Lawsuit filed

    In a legal dispute involving Gilead Sciences, the U.S. Department of Health and Human Services filed a lawsuit concerning patent rights to Truvada and Descovy for HIV prevention. The suit asserts that the government owns the relevant PrEP patents. These claims are allegations made in the litigation and do not constitute a court determination. The event concerns a patent dispute over HIV prevention drugs and the asserted ownership of PrEP-related patents.

    Company response

    • Denial — Gilead

      In response, Gilead said the government’s patent claims were “invalid.”

    Source excerpt

    • The lawsuit, filed Wednesday in U.S. District Court for the District of Delware, alleges that CDC researchers began studying the preventive use of HIV treatment drugs — like tenofovir, or TDF, and emtricitabine, FTC, the two compounds in a Truvada tablet — as early as 1998, before Gilead sought a patent.
    • Crucially, the lawsuit alleges that the government owns the PrEP patent for both Truvada and Descovy, Gilead’s next generation PrEP approved last month, setting up the possibility that both HIV prevention drugs could see drastic price reductions.
    • In response, Gilead said the government’s patent claims were “invalid.”
    Source